TABLE 3.
Longitudinal analysis of blood eosinophils (ln‐transformed) and lung function growth
| Longitudinal analysis | FEV1%pred | FVC%pred | FEV1/FVC%pred | |||
|---|---|---|---|---|---|---|
| β (95% CI) | p | β (95% CI) | p | β (95% CI) | p | |
| Asthma cohort | −0.66 (−1.11, −0.20) | <.01 | −0.40 (−0.75, −0.05) | .025 | −0.33 (−0.68, 0.02) | .07 |
| PIAMA non‐asthmatic | 0.21 (0.00, 0.40) | .04 | 0.10 (−0.00, 0.31) | .33 | 0.10 (−0.02, 0.22) | .11 |
| PIAMA asthmatic | 0.00 (−0.91, 0.91) | .99 | −0.26 (−1.14, 0.61) | .55 | 0.19 (−0.60, 0.99) | .63 |
| PIAMA asthmatic—no ICS | 0.03 (−0.89, 0.96) | .94 | −0.27 (−1.20, 0.67) | .57 | 0.23 (−0.62, 10.09) | .59 |
PIAMA: adjusted for sex, parental education and atopy, respiratory infections within 3 weeks of measurement, bronchial hyper‐responsiveness (BHR) and sensitization at age 8. Asthma cohort was adjusted for sex and sensitization. Reference equations for lung function measurement obtained from the Global Lung Function Initiative. 20 β: Change in % predicted lung function for every 1‐unit increase in ln (blood eosinophils). For unadjusted analysis, please see Tables S6 and S7. ICS—inhaled corticosteroid: defined as use within the last 12 months at the 8‐year measurement point.